Oncolytics Biotech Inc. (ONCY)
NasdaqCM · USD · Healthcare · Biotechnology
$0.4732 (-5.79%) as of
Key statistics
- Market cap
- 62.05M
- Forward P/E
- -2.37
- EPS (TTM)
- -0.3500
- Dividend yield
- 0.00%
- 52-week range
- 0.4400 – 1.3200
- Beta
- 1.15
- Profit margin
- 0.00%
- Analyst target
- $4.21
- Volume
- 694.53k
About Oncolytics Biotech Inc.
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- San Diego, CA, United States
- Employees
- 29
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.